<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">16434984</article-id><article-id pub-id-type="pmc">2361121</article-id><article-id pub-id-type="pii">6602937</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6602937</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Monocytes and neutrophils as &#x02018;bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma &#x02013; results from a randomised phase II trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Donskov</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hokland</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Marcussen</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Torp Madsen</surname><given-names>H H</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>von der Maase</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Oncology, Aarhus University Hospital, Denmark</aff><aff id="aff2"><label>2</label>Department of Medical Microbiology and Immunology, University of Aarhus, Denmark</aff><aff id="aff3"><label>3</label>Department of Pathology, Aarhus University Hospital, Denmark</aff><aff id="aff4"><label>4</label>Department of Radiology, Aarhus University Hospital, Denmark</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:fd@microbiology.au.dk">fd@microbiology.au.dk</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>01</month><year>2006</year></pub-date><pub-date pub-type="ppub"><day>30</day><month>01</month><year>2006</year></pub-date><volume>94</volume><issue>2</issue><fpage>218</fpage><lpage>226</lpage><history><date date-type="received"><day>23</day><month>09</month><year>2005</year></date><date date-type="rev-recd"><day>28</day><month>11</month><year>2005</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2005</year></date></history><copyright-statement>Copyright 2006, Cancer Research UK</copyright-statement><copyright-year>2006</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Histamine (HDC) inhibits formation and release of phagocyte-derived reactive oxygen species, and thereby protects natural killer (NK) and T cells against oxidative damage. Thus, the addition of histamine may potentially improve the efficacy of interleukin-2 (IL-2). We have explored this potential mechanism clinically in two randomised phase II trials in metastatic renal cell carcinoma (mRCC). In parallel with the clinical trial in Denmark (<italic>n</italic>&#x0003d;63), we obtained serial blood samples and tumour biopsies searching for a potential histamine effect <italic>in situ</italic>. At baseline and on-treatment weeks 3 and 8, we monitored the &#x02018;good guys' (i.e. NK and T cells) and &#x02018;bad guys' (i.e. monocytes&#x0002f;macrophages and neutrophils) simultaneously in blood (<italic>n</italic>&#x0003d;59) and tumour tissue (<italic>n</italic>&#x0003d;44). Patients with high number of monocytes and neutrophils in peripheral blood had very poor survival, with apparently no benefit from either IL-2 alone or IL-2&#x0002f;HDC treatment. Blood monocytes (<italic>r</italic>&#x0003d;&#x02212;0.36, <italic>P</italic>&#x0003d;0.01) and neutrophils (<italic>r</italic>&#x0003d;&#x02212;0.46, <italic>P</italic>&#x0003d;0.001) were negatively correlated with cytotoxicity, whereas blood NK cells were positively correlated with cytotoxicity (<italic>r</italic>&#x0003d;0.39, <italic>P</italic>&#x0003d;0.002). Treatment with IL-2 alone resulted in a significantly higher number of circulating monocytes (<italic>P</italic>&#x0003d;0.037) and intratumoral macrophages (<italic>P</italic>&#x0003d;0.005) compared with baseline. In contrast, IL-2&#x0002f;HDC resulted in an unchanged number of circulating monocytes and intratumoral macrophages, and in addition, a significantly increased number of intratumoral CD56<sup>&#x0002b;</sup> NK cells (<italic>P</italic>&#x0003d;0.008) and CD8<sup>&#x0002b;</sup> T cells (<italic>P</italic>&#x0003d;0.019) compared with baseline. The study provides evidence that circulating monocytes and neutrophils are powerful negative prognostic factors for IL-2-based immunotherapy and establishes a biological rationale for the potential use of histamine in conjunction with IL-2 in mRCC.</p></abstract><kwd-group><kwd>renal cell carcinoma</kwd><kwd>interleukin-2</kwd><kwd>histamine dihydrochloride, oxidative stress</kwd></kwd-group></article-meta></front><body><p>The observation that many cancers in adults arise in the setting of chronic inflammation has opened up a research field that has been crucial for our understanding and ultimately has established a new paradigm (<xref ref-type="other" rid="bib48">Vakkila and Lotze, 2004</xref>). Solid tumours are not just composed of malignant cells (<xref ref-type="other" rid="bib18">Hanahan and Weinberg, 2000</xref>), but are complex tissues in which tumour cells have attracted and educated tumour-infiltrating leucocytes (especially macrophages, neutrophils and mast cells) to serve as active collaborators (<xref ref-type="other" rid="bib9">Coussens and Werb, 2001</xref>; <xref ref-type="other" rid="bib37">Murdoch <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib41">Pollard, 2004</xref>). Through the production of growth factors, proteases, angiogenic mediators and reactive oxygen species (ROS), tumour-educated macrophages promote tumour growth, angiogenesis, metastasis and genomic instability (<xref ref-type="other" rid="bib5">Balkwill and Mantovani, 2001</xref>; <xref ref-type="other" rid="bib10">Coussens and Werb, 2002</xref>; <xref ref-type="other" rid="bib29">Lin and Pollard, 2004</xref>; <xref ref-type="other" rid="bib49">Wyckoff <italic>et al</italic>, 2004</xref>; <xref ref-type="other" rid="bib8">Chen <italic>et al</italic>, 2005</xref>). Moreover, monocyte&#x0002f;macrophage-generated ROS are highly toxic to antitumour lymphocytes such as natural killer (NK) cells and T cells with the result that these cells undergo apoptosis (<xref ref-type="other" rid="bib19">Hansson <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib28">Kono <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib32">Malmberg, 2004</xref>).</p><p>Monocytes&#x0002f;macrophages and neutrophils therefore represent an important drug-target for cancer treatment, with the aim of reducing the number and&#x0002f;or function of these cells. Extensive laboratory work for a decennium has identified histamine dihydrochloride (HDC) as an anti-phagocyte drug-candidate (<xref ref-type="other" rid="bib21">Hellstrand, 2002</xref>). Targeting NADPH-oxidase through binding to the H<sub>2</sub>-receptor on monocytes (<xref ref-type="other" rid="bib24">Hellstrand and Hermodsson, 1986</xref>) and neutrophils (<xref ref-type="other" rid="bib6">Betten <italic>et al</italic>, 2003</xref>), HDC specifically blocks the formation and release of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), thereby protecting NK and T cells from oxygen radical-induced inhibition and apoptosis (<xref ref-type="other" rid="bib22">Hellstrand <italic>et al</italic>, 1994</xref>). Thus, NK and T cells remain viable and responsive to interleukin-2 (IL-2) (<xref ref-type="other" rid="bib23">Hellstrand <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib25">Hellstrand and Hermodsson, 1990</xref>; <xref ref-type="other" rid="bib3">Asea <italic>et al</italic>, 1996</xref>). IL-2 has no direct impact on tumour cells (<xref ref-type="other" rid="bib42">Rosenberg, 2001</xref>) but requires NK and T-cells for tumourlysis (<xref ref-type="other" rid="bib12">Donskov <italic>et al</italic>, 2002a</xref>, <xref ref-type="other" rid="bib11">2004a</xref>, <xref ref-type="other" rid="bib15">2004b</xref>). Thus, the addition of histamine may potentially improve the efficacy of IL-2.</p><p>We have explored this potential mechanism clinically in a randomised phase II trial in metastatic renal cell carcinoma (mRCC) (<xref ref-type="other" rid="bib13">Donskov <italic>et al</italic>, 2005</xref>). As a supplement to the clinical trial in Denmark, the present biological study was initiated to search for a potential histamine effect <italic>in situ</italic>.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patients and treatment</title><p>Two randomised phase II trials of IL-2 with and without HDC were run in parallel, one in Aarhus, Denmark and one in Manchester, United Kingdom (<xref ref-type="other" rid="bib13">Donskov <italic>et al</italic>, 2005</xref>). Only patients randomised in the Danish study were included in the blood and tumour study. The local ethics committee approved the study. All subjects gave written informed consent before blood samples and tumour biopsies. Study design, data accrual, data analyses and manuscript preparation were performed entirely by the authors.</p><p>In order to be able to correlate the baseline and on-treatment blood and tumour parameters with the <italic>biological</italic> effect of IL-2 with and without histamine, it was predefined that only patients receiving at least 80&#x00025; of the scheduled drug dose within the first treatment course were assessable for the present analyses.</p><p>Patients were consecutively randomised to receive either IL-2&#x0002f;HDC or IL-2 alone. One cycle consisted of IL-2 (Aldesleukin, rIL-2, Proleukin&#x000ae;, Chiron, The Netherlands) as a fixed dose, 18 MIU s.c. once daily, 5 days per week for 3 weeks followed by 2 weeks rest. Histamine dihydrochloride (HDC, Ceplene&#x02122;, supplied by Maxim Pharmaceuticals Inc., San Diego, USA), 1.0&#x02009;mg was added twice daily, concomitantly with IL-2. Patients were evaluated for objective response, according to standard WHO criteria (<xref ref-type="other" rid="bib35">Miller <italic>et al</italic>, 1981</xref>), every two cycles (10 weeks). A maximum of four treatment cycles was given.</p></sec><sec><title>Tumour samples</title><p>Core needle biopsies (18&#x02009;G cutting needle) were collected by standard ultrasound-guided procedures before treatment (baseline) and at day 2 in weeks 3 and 8. The week 3 and week 8 time points were selected to coincide with routine outpatient visit, according to the immunotherapy schedule. A total of 98 biopsies were obtained (<xref rid="tbl1" ref-type="table">Table 1</xref>) at baseline from 44 patients (IL-2&#x0002f;HDC, <italic>n</italic>&#x0003d;21; IL-2, <italic>n</italic>&#x0003d;23), at week 3 from 29 patients (IL-2&#x0002f;HDC, <italic>n</italic>&#x0003d;14; IL-2, <italic>n</italic>&#x0003d;15) and at week 8 from 25 patients (IL-2&#x0002f;HDC, <italic>n</italic>&#x0003d;12; IL-2, <italic>n</italic>&#x0003d;13). Based on well-known prognostic factors of MSKCC (<xref ref-type="other" rid="bib36">Motzer <italic>et al</italic>, 1999</xref>), there were no significant differences between the baseline patient group and the week 3 or the week 8 group, <italic>P</italic>&#x0003d;0.8 and <italic>P</italic>&#x0003d;0.15, respectively, (Fisher's exact test). There was no significant difference between tumour histology types (IL-2&#x0002f;HDC, clear cell RCC 82&#x00025;; IL-2, clear cell RCC 88&#x00025;) (<italic>P</italic>&#x0003d;0.49).</p><p>Biopsies were performed from accessible tumour locations: kidney, <italic>n</italic>&#x0003d;42; liver, <italic>n</italic>&#x0003d;17; lung&#x0002f;pleura&#x0002f;chest wall, <italic>n</italic>&#x0003d;13; abdominal&#x0002f;pelvic soft tissue, <italic>n</italic>&#x0003d;10; lymph node, <italic>n</italic>&#x0003d;9; subcutis, <italic>n</italic>&#x0003d;7; kidney bed, <italic>n</italic>&#x0003d;6; and muscle, <italic>n</italic>&#x0003d;2; some patients had biopsies from more than one location. On-treatment biopsies were obtained from the same tumour as the baseline biopsy. Unfortunately, it showed up that none of the subsequent CR patients had accessible baseline tumours for core needle biopsies. Thus, these CR patients were not included in the statistical analyses for the tumour variables but were, however, included in the statistical analyses for the blood variables.</p></sec><sec><title>Immunohistochemistry</title><p>Immunohistochemistry used standard procedures, as described in our previous studies (<xref ref-type="other" rid="bib12">Donskov <italic>et al</italic>, 2002a</xref>, <xref ref-type="other" rid="bib11">2004a</xref>). Paraffin sections were stained with monoclonal antibodies from DakoCytomation, Denmark, CD8 (M7103 1&#x02009;:&#x02009;100), CD20 (M0755 1&#x02009;:&#x02009;500); NovoCastra, Denmark, CD4 (NCL-CD4-1F6 1&#x02009;:&#x02009;50), CD56 (NCL-CD56-1B6 1&#x02009;:&#x02009;40), MACRO (NCL-MACRO 1&#x02009;:&#x02009;80); Pharmingen, Denmark, CD57 (33251A 1&#x02009;:&#x02009;500), CD66b (33731A 1&#x02009;:&#x02009;100) and Ramcon, Denmark, zeta (IM2549 1&#x02009;:&#x02009;20). Primary antibodies were detected using the Envision-peroxidase system (K4000, DakoCytomation). All staining was performed in a TechMate automatic immunohistochemistry staining machine, (DakoCytomation, Denmark).</p></sec><sec><title>Immunohistochemical evaluation</title><p>Intratumoural immune cells were counted by an objective and reproducible stereological method (<xref ref-type="other" rid="bib17">Gundersen <italic>et al</italic>, 1988</xref>). A computer-generated unbiased counting frame was used to perform measurements. The first field of vision was chosen at random, after which the computer systematically sampled the subsequent fields of vision within the entire tumour biopsy. Necrosis, artefacts and fibrous areas were omitted. Using a &#x000d7; 40 objective, a total number of 40 fields (4951&#x02009;<italic>&#x003bc;</italic>m<sup>2</sup> each) were counted, if the size of the tumour biopsy allowed for it. Only cells showing specific surface staining, a visible nucleus and location within the counting frame were counted as positive. The mean number of cells&#x02009;mm<sup>&#x02212;2</sup> tumour tissue was assessed for each patient. Staining was analysed blinded by one observer. Selected sections were counted blinded by a second experienced observer (NM) and a high level of reproducibility was demonstrated, as previously reported (<xref ref-type="other" rid="bib11">Donskov <italic>et al</italic>, 2004a</xref>).</p></sec><sec><title>Blood samples</title><p>Peripheral blood mononuclear cells were obtained (<xref rid="tbl1" ref-type="table">Table 1</xref>) and isolated from lithium-heparinized whole blood samples by Ficoll&#x02013;Paque (Pharmacia Biotech, Uppsala, Sweden) gradient separation, washed twice and cryopreserved at &#x02212;135&#x000b0;C until use. Cytolytic activity was determined by standard 4-h <sup>51</sup>Cr-release assay against K562 target, as previously reported in detail (<xref ref-type="other" rid="bib12">Donskov <italic>et al</italic>, 2002a</xref>). Differential blood cell counts were determined by standard Coulter counter technique (Coulter STKS) in the clinical chemistry laboratory.</p><p>Cell surface phenotypes were determined by flow cytometry using a Coulter XL-2 flow cytometer (Coulter Electronics, Florida). Data were analysed using the Flow-Jo software (Treestar, San Carlos, CA). Direct fluorochrome-conjugated antibodies (FITC or PE) were purchased from DakoCytomation, Denmark (CD3, CD4, CD8, CD20) and Becton Dickinson, Denmark (CD16, CD56, CD57, CD69). Intracellular zeta expression was investigated on permeabilised cells, using 2H2D9 (TIA-2) PE-conjugated MoAb (Ramcon, Denmark). Relevant isotype controls were purchased from DakoCytomation.</p></sec><sec><title>Statistics</title><p>Overall survival time was measured from the first day of treatment until death or last follow-up evaluation. The relationship between assessed parameters and treatment arm was evaluated using the nonparametric Mann&#x02013;Whitney <italic>U</italic>-test. The significance of changes from baseline to week 3 or to week 8 was assessed using the Wilcoxon signed rank test for paired samples. Differences in patient characteristics and response rates were analysed by Fisher's exact test. The cumulated survival rate was analysed by Kaplan&#x02013;Meier and the log-rank test was used to analyse for survival differences among subgroups of patients. The median follow-up period was 43 months (range 32&#x02013;51 months). No patients were lost to follow-up. Data were updated April 14, 2005. Statistical analyses were performed using SPSS v11.0.</p></sec></sec><sec><title>RESULTS</title><sec><title>Overall clinical outcome</title><p>Between August 2000 and August 2002, 63 patients with mRCC were enrolled in a Danish single-centre randomised phase II trial. Thirty-three patients were randomly assigned to IL-2&#x0002f;HDC therapy and 30 to IL-2 alone. The clinical outcome of this and a parallel UK study has been published separately (<xref ref-type="other" rid="bib13">Donskov <italic>et al</italic>, 2005</xref>). In summary, our Danish study showed a statistically significant 1-year survival benefit (76 <italic>vs</italic> 47&#x00025;, <italic>P</italic>&#x0003d;0.03) and a trend towards an improved median survival time (18.3 <italic>vs</italic> 11.4 months, <italic>P</italic>&#x0003d;0.07) and an improved clinical benefit (CR&#x0002b;PR&#x0002b;SD) (58 <italic>vs</italic> 37&#x00025;, <italic>P</italic>&#x0003d;0.10) in favour of IL-2&#x0002f;HDC compared with IL-2 alone. Overall response rate was not significantly different between the two treatment groups.</p><p>The present analyses were based on 59 out of the 63 patients, receiving at least 80&#x00025; of the scheduled drug dose in the first treatment course, in order to assess the <italic>biological</italic> effect of IL-2 with and without histamine in relation to baseline and on-treatment blood samples and tumour-tissue biopsies.</p><p>Patient characteristics were generally well balanced across treatment arms, although slightly more patients on the IL-2 arm had liver metastases and more patients on the IL-2&#x0002f;HDC arm were males (<xref rid="tbl2" ref-type="table">Table 2</xref>). These differences were not statistically significant (<italic>P</italic>&#x0003d;0.18 and <italic>P</italic>&#x0003d;0.054, respectively).</p></sec><sec><title>Clinical outcome stratified for blood monocytes, neutrophils, NK and T cells</title><p>The prognostic impact of monocytes, neutrophils, NK and T-cells was analysed. As IL-2 treatment may induce considerably changes in the number and function of immune cells, baseline as well as on-treatment week 3 and week 8 values were correlated with treatment outcome. By keeping the on-treatment analyses de-linked from baseline, we evaluated the potential prognostic impact of high <italic>vs</italic> low numbers of immune cells, independently of previous measurements &#x02013; with special emphasis on a possible histamine effect. Dichotomy of the variables was done at the median values. For baseline neutrophils, the median value (5.46) was close to the predefined cutoff level of 6.0 &#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup> (<xref ref-type="other" rid="bib30">Lopez <italic>et al</italic>, 1996</xref>), which therefore was used as cutoff for the analyses. High levels of monocytes at week 8 (<italic>P</italic>&#x0003d;0.009) and neutrophils at baseline and at week 8 (<italic>P</italic>&#x0003d;0.014 and <italic>P</italic>&#x0003d;0.0002, respectively) were correlated with short survival (<xref ref-type="fig" rid="fig1">Figure 1</xref>). High levels of NK cells at baseline were correlated with long survival, however, of borderline significance (<italic>P</italic>&#x0003d;0.08). Baseline monocytes and NK cells at week 8 were not significantly correlated with survival. Further stratification by treatment assignment is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. Patients with high number of monocytes and neutrophils in peripheral blood had a very poor survival, with apparently no benefit from either IL-2 alone or IL-2&#x0002f;HDC treatment. In contrast, survival was significantly improved in the IL-2&#x0002f;HDC group compared with the IL-2 alone group in patients with low number of baseline monocytes (<italic>P</italic>&#x0003d;0.005), low number of baseline neutrophils (<italic>P</italic>&#x0003d;0.043), low number of neutrophils at week 8 (<italic>P</italic>&#x0003d;0.041) and high number of NK cells at week 8 (<italic>P</italic>&#x0003d;0.025). The same trend, however, of only borderline significance, was seen in patients with low monocytes at week 8 (<italic>P</italic>&#x0003d;0.07) and low NK cells at week 0 (<italic>P</italic>&#x0003d;0.07) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Monocytes, neutrophils and NK cells, measured on week 3, showed the same trend as obtained at baseline and week 8 (data not shown).</p><p>We also evaluated blood lymphocyte subsets expressing CD4<sup>&#x0002b;</sup>, CD8<sup>&#x0002b;</sup>, CD56<sup>&#x0002b;</sup>, CD56<sup>dim</sup>, CD56<sup>bright</sup>, CD3<sup>&#x02212;</sup>CD56<sup>&#x0002b;</sup>, CD56<sup>&#x0002b;</sup>CD57<sup>&#x0002b;</sup> and CD57<sup>&#x0002b;</sup>. In general, the survival curves for these lymphocyte subsets were similar to the survival curves for the CD16<sup>&#x0002b;</sup>56<sup>&#x0002b;</sup>NK-cell. Thus, no significant survival differences were observed between &#x02018;high' and &#x02018;low' lymphocyte subsets. However, long-term survival was especially noted in patients treated with IL-2&#x0002f;HDC (data not shown).</p></sec><sec><title>Circulating blood phagocytes</title><p>The potential histamine effect on circulating phagocytes in peripheral blood was assessed <italic>in situ</italic> in blood samples obtained at baseline and during therapy at weeks 3 and 8. Non-PD patients (CR&#x0002b;PR&#x0002b;SD) treated with IL-2&#x0002f;HDC had unchanged number of circulating monocytes during treatment compared with baseline. In contrast, non-PD patients treated with IL-2 alone had significantly increased numbers at weeks 3 (<italic>P</italic>&#x0003d;0.037) and 8 (<italic>P</italic>&#x0003d;0.043) compared with baseline (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Moreover, all PD patients had significantly increased monocyte numbers at weeks 3 and 8 compared with baseline, both for patients treated with IL-2&#x0002f;HDC (<italic>P</italic>&#x0003d;0.01 and <italic>P</italic>&#x0003d;0.008, respectively) and for patients treated with IL-2 alone (<italic>P</italic>&#x0003d;0.01 and <italic>P</italic>&#x0003d;0.05, respectively), data not shown. Circulating neutrophils were evaluated similarly; however, no statistically significant differences were found.</p></sec><sec><title>Tumour-infiltrating immune cells</title><p>The potential histamine effect on the leucocyte subsets infiltrating the tumour tissue was assessed <italic>in situ</italic> in tumour core-needle biopsies obtained at baseline and during treatment at weeks 3 and 8. A total of 98 tumour biopsies were analysed (IL-2&#x0002f;HDC, <italic>n</italic>&#x0003d;47 and IL-2, <italic>n</italic>&#x0003d;51) (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Patients treated with IL-2&#x0002f;HDC had significantly higher number of intratumoural CD56<sup>&#x0002b;</sup> NK cells at weeks 3 (<italic>P</italic>&#x0003d;0.008) and 8 (<italic>P</italic>&#x0003d;0.016) and also higher number of intratumoural CD8<sup>&#x0002b;</sup> T cells at week 8 (<italic>P</italic>&#x0003d;0.019) compared with baseline. In contrast, intratumoural macrophage numbers remained unchanged at weeks 3 and 8 compared with baseline (<xref ref-type="fig" rid="fig4">Figure 4</xref>). In comparison, patients treated with IL-2 alone had no increased intratumoural NK or T cells, but did show a significantly increased number of intratumoural macrophages at week 8 compared with baseline (<italic>P</italic>&#x0003d;0.005).</p><p>Intratumoural neutrophils showed no significant differences between treatment groups (data not shown)</p></sec><sec><title>Functional assays</title><p>An activation receptor for NK cells is CD16 (<xref ref-type="other" rid="bib26">Herberman, 2002</xref>). Therefore, we assessed CD16<sup>&#x0002b;</sup>CD56<sup>&#x0002b;</sup>NK cells in peripheral blood as a functional assay. The number of CD16<sup>&#x0002b;</sup>56<sup>&#x0002b;</sup>NK cells increased median 350&#x00025; (week 3) and 398&#x00025; (week 8) compared with baseline values (<italic>P</italic>&#x0003c;0.001 and <italic>P</italic>&#x0003c;0.001, respectively), however, with no significant difference between the IL-2&#x0002f;HDC and the IL-2 alone group. In parallel, <italic>in vitro</italic> cytotoxicity increased median 121&#x00025; (week 3) and 155&#x00025; (week 8) compared with baseline values. There was a significantly positive correlation between blood CD16<sup>&#x0002b;</sup>56<sup>&#x0002b;</sup> NK cells and cytotoxicity at baseline (Spearman's <italic>r</italic>&#x0003d;0.39, <italic>P</italic>&#x0003d;0.002), week 3 (<italic>r</italic>&#x0003d;0.31, <italic>P</italic>&#x0003d;0.02) and week 8 (<italic>r</italic>&#x0003d;0.29, <italic>P</italic>&#x0003d;0.03) (<xref ref-type="fig" rid="fig5">Figure 5</xref>). In contrast, there was a significantly negative correlation between blood neutrophils and cytotoxicity at week 3 (<italic>r</italic>&#x0003d;&#x02212;0.29, <italic>P</italic>&#x0003d;0.03) and week 8 (<italic>r</italic>&#x0003d;&#x02212;0.46, <italic>P</italic>&#x0003d;0.001) and also between blood monocytes and cytotoxicity at week 8 (<italic>r</italic>&#x0003d;&#x02212;0.36, <italic>P</italic>&#x0003d;0.01) (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The expression of the blood lymphocyte activation marker CD69 was significantly higher at week 8 compared with baseline in patients treated with IL-2&#x0002f;HDC (<italic>P</italic>&#x0003d;0.001), whereas no increase was observed in patients treated with IL-2 alone. CD3-zeta chain expression in blood and tumour did not show a statistically significant histamine effect compared with the effect of IL-2 alone.</p></sec></sec><sec><title>DISCUSSION</title><p>The results of the present biological part of our prospective randomised phase II trial provide evidence for circulating monocytes and neutrophils as negative prognostic factors for IL-2-based immunotherapy. Clearly, patients with high numbers of monocytes and neutrophils in peripheral blood had very poor survival, with apparently no impact of either IL-2-alone or IL-2 plus histamine treatment. Blood monocytes and neutrophils were negatively correlated with cytotoxicity, whereas blood NK cells were positively correlated with cytotoxicity, although not all differences achieved statistical significance, which may be due to the relatively small patient number. Thus, our data are highly supportive of the oxidative stress hypothesis formulated by <xref ref-type="other" rid="bib21">Hellstrand <italic>et al</italic> (2002</xref>). Previously, three large studies of prognostic factors for IL-2 based immunotherapy in mRCC, including a total of 1422 patients, have all identified baseline-elevated neutrophils and biological signs of inflammation as poor prognostic factors (<xref ref-type="other" rid="bib30">Lopez <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib38">Negrier <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib4">Atzpodien <italic>et al</italic>, 2003</xref>). Moreover, a reduction in blood monocytes during IL-2 treatment has been correlated with clinical response (<xref ref-type="other" rid="bib27">Hermann <italic>et al</italic>, 1991</xref>). However, these studies were all purely descriptive with no ability to explain their findings. It is particularly noteworthy that the present study not only identifies baseline and on-treatment-elevated neutrophils and monocytes as poor prognostic factors, as we also did in a previous study (<xref ref-type="other" rid="bib11">Donskov <italic>et al</italic>, 2004a</xref>), but offers an explanation of these findings by supporting the oxidative stress hypothesis. Our results therefore add to the understanding of how reactive oxygen-radicals influence the biological <italic>in vivo</italic> activity of immune cells during IL-2 based immunotherapy.</p><p>Chronic immune activation and chronic inflammation have long been suspected to be promoters of malignancy (<xref ref-type="other" rid="bib5">Balkwill and Mantovani, 2001</xref>; <xref ref-type="other" rid="bib10">Coussens and Werb, 2002</xref>). Among macrophage and neutrophils products, ROS may not only induce genomic instability (<xref ref-type="other" rid="bib40">O'Byrne and Dalgleish, 2001</xref>), but also damage antitumour immune effector cells (<xref ref-type="other" rid="bib46">Seaman <italic>et al</italic>, 1982</xref>; <xref ref-type="other" rid="bib22">Hellstrand <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib19">Hansson <italic>et al</italic>, 1996</xref>). Intratumoural macrophages isolated from melanoma metastases inhibit NK-cell function by the release of ROS (<xref ref-type="other" rid="bib28">Kono <italic>et al</italic>, 1996</xref>). Intratumoural NK and T cells isolated from mRCC show signs of oxidative damage (<xref ref-type="other" rid="bib16">Finke <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib47">Tartour <italic>et al</italic>, 1995</xref>). IL-2 cannot activate NK cells <italic>in vitro</italic> in the presence of monocytes or macrophages (<xref ref-type="other" rid="bib25">Hellstrand and Hermodsson, 1990</xref>). Based on these observations, it seems convincing that the observed survival differences for patients in the present study are caused by a phagocyte characteristic, namely the production of ROS, although we did not perform any direct measurements of ROS as purification methods and laboratory processes are difficult to perform without inducing stimulation in monocytes or neutrophils. Further investigation of the relation between phagocytes, NK cells, T cells and ROS in blood and tumour tissue is warranted, including direct measurements of apoptosis and ROS levels.</p><p>Our data support a novel treatment strategy involving the blocking of phagocyte-generated ROS by histamine, thereby protecting NK and T cells from apoptosis and, thus, synergising with IL-2 in inducing NK- and T-cell activation (<xref ref-type="other" rid="bib25">Hellstrand and Hermodsson, 1990</xref>; <xref ref-type="other" rid="bib23">Hellstrand <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib3">Asea <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib20">Hansson <italic>et al</italic>, 1999</xref>). Clearly, with regard to the &#x02018;good guys', treatment with IL-2&#x0002f;HDC resulted in significantly higher numbers of intratumoural NK and CD8<sup>&#x0002b;</sup>T cells during treatment compared with baseline. In contrast, treatment with IL-2 alone did not result in an increased number of intratumoural NK or T cells. Moreover, with regard to the &#x02018;bad guys', treatment with IL-2&#x0002f;HDC resulted in an unchanged number of circulating monocytes and intratumoural macrophages during treatment compared with baseline, whereas treatment with IL-2-alone did not prevent a significantly higher number of both circulating monocytes and intratumoural macrophages developing during treatment compared with baseline. It should be noted that low numbers of monocytes and neutrophils or high number of NK cells in peripheral blood were correlated with long-term survival. In these subgroups, a substantially increased survival rate was observed in patients treated with IL-2&#x0002f;HDC compared with patients treated with IL-2 alone. Thus, targeting H<sub>2</sub>O<sub>2</sub> by histamine seems to enhance the antitumour activity of IL-2 <italic>in situ</italic> in a subgroup of patients. Recently, a superoxide dismutase mimetic, M40403, targeting superoxide (O<sub>2</sub><sup>&#x02022;&#x02212;</sup>) was reported to enhance the antitumour action of IL-2 in mice models (<xref ref-type="other" rid="bib44">Samlowski <italic>et al</italic>, 2003</xref>). As a result, developing and assessing drugs that block the generation of oxygen radicals as an adjunct to IL-2 is a viable therapeutic opportunity in renal cell cancer.</p><p>A randomised phase II trial of IL-2 with and without HDC in mRCC was run independently in Manchester, UK in parallel with the present trial (<xref ref-type="other" rid="bib13">Donskov <italic>et al</italic>, 2005</xref>). The two studies had exactly the same clinical design and patient selection criteria. The outcome of the individual studies differed as the Danish study (<italic>n</italic>&#x0003d;63) showed a trend towards improved efficacy in favour of IL-2&#x0002f;HDC, whereas the UK study (<italic>n</italic>&#x0003d;41) was negative for all end points (<xref ref-type="other" rid="bib13">Donskov <italic>et al</italic>, 2005</xref>). So, based on the randomised trials by themselves, no clear-cut effect of adding histamine to IL-2 was recognized. However, by the present biological analyses, a potential effect of histamine was clearly demonstrated, emphasising the value of accompanying clinical trials with blood and tumour tissue assessments. Indeed, the present assessment of the oxidative stress hypothesis in blood and tumour tissue is the first to establish a biological rationale &#x02013; in humans &#x02013; for the use of histamine in conjunction with IL-2 despite several clinical trials (<xref ref-type="other" rid="bib7">Brune and Hellstrand, 1996</xref>; <xref ref-type="other" rid="bib34">Mellqvist <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib1">Agarwala <italic>et al</italic>, 2002</xref>, <xref ref-type="other" rid="bib2">2004</xref>; <xref ref-type="other" rid="bib31">Lurie <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib45">Schmidt <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib14">Donskov <italic>et al</italic>, 2002b</xref>). Previously, we have tested histamine in mRCC with <italic>low-dose</italic> IL-2 and interferon-alpha (IFN) (<xref ref-type="other" rid="bib14">Donskov <italic>et al</italic>, 2002b</xref>) with no difference in treatment groups observed (<xref ref-type="other" rid="bib11">Donskov <italic>et al</italic>, 2004a</xref>). However, the question of whether histamine might improve efficacy with higher doses of IL-2 formed the basis for the present randomised phase II study. Thus, in the present study, we have doubled the dose of IL-2 compared to that in our first IL-2&#x0002f;IFN&#x0002f;Histamine-study and the applied IL-2 dose can be considered to be an intermediate dose level.</p><p>Since its introduction to the clinic in 1985 (<xref ref-type="other" rid="bib43">Rosenberg <italic>et al</italic>, 1985</xref>), IL-2 remains the only established immunotherapy approved by the US Food and Drug Administration for the treatment of metastatic melanoma and mRCC. However, despite 20 years of clinical trials, no combination therapy has proved better than IL-2 treatment alone in terms of long-term survival (<xref ref-type="other" rid="bib39">Negrier <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib33">McDermott <italic>et al</italic>, 2005</xref>). Thus, cancer immunotherapy is most dependent on the application of advances in knowledge of basic science and its translation to the clinic. The present study indicates a direction for future clinical immunotherapy efforts.</p><p>In conclusion, our study provides evidence for circulating monocytes and neutrophils as powerful negative prognostic factors for IL-2-based immunotherapy and establishes a biological rationale for the potential use of histamine in conjunction with IL-2 in mRCC. However, patient numbers are too small to make definitive conclusions. Thus, a large confirmatory randomised phase III trial of IL-2 with and without histamine in mRCC appropriately stratified for monocytes and neutrophils in blood and tumour tissue is warranted.</p></sec></body><back><ack><p>We wish to thank Karin Vestergaard for cutting sections, Tom Nordfeld for help with immunohistochemistry and Anja Balmer and Bettina Grumsen for help with cytotoxicity and flow cytometry assays. Staff members at the Department of Oncology are acknowledged for their careful management of the patients.</p><p>This study was supported by grants from the Danish Research Council, Max and Inger Woerzner Foundation, The Radium Center Research Foundation, Gerda and Aage Haench's Foundation, The Beckett Foundation, Preben and Anna Simonsens Foundation, Agnes Niebuhr Anderssons Foundation, Johannes Fogh-Nielsen Foundation, Agnes and Poul Friis Foundation, Erland Richard Frederiksen Foundation, Jens C. Christoffersen Foundation, Kristian Kjaer Foundation, Hans and Nora Burchard's Foundation, The Danish Medical Association Research Fund and The Danish Cancer Society (MH).</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Glaspy</surname><given-names>J</given-names></name><name><surname>O'Day</surname><given-names>SJ</given-names></name><name><surname>Mitchell</surname><given-names>M</given-names></name><name><surname>Gutheil</surname><given-names>J</given-names></name><name><surname>Whitman</surname><given-names>E</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Hersh</surname><given-names>E</given-names></name><name><surname>Feun</surname><given-names>L</given-names></name><name><surname>Belt</surname><given-names>R</given-names></name><name><surname>Meyskens</surname><given-names>F</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Gehlsen</surname><given-names>KR</given-names></name><name><surname>Naredi</surname><given-names>P</given-names></name></person-group><article-title>Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>125</fpage><lpage>133</lpage><!--PubMed citation query: 'J Clin Oncol||20|125||bib1|'--><pub-id pub-id-type="pmid">11773161</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Gehlsen</surname><given-names>K</given-names></name><name><surname>Naredi</surname><given-names>P</given-names></name></person-group><article-title>Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis</article-title><source>Cancer Immunol Immunother</source><year>2004</year><volume>53</volume><fpage>840</fpage><lpage>841</lpage><!--PubMed citation query: 'Cancer Immunol Immunother||53|840||bib2|'--><pub-id pub-id-type="pmid">15127238</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asea</surname><given-names>A</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name></person-group><article-title>Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice</article-title><source>Scand J Immunol</source><year>1996</year><volume>43</volume><fpage>9</fpage><lpage>15</lpage><!--PubMed citation query: 'Scand J Immunol||43|9||bib3|'--><pub-id pub-id-type="pmid">8560202</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Atzpodien</surname><given-names>J</given-names></name><name><surname>Royston</surname><given-names>P</given-names></name><name><surname>Wandert</surname><given-names>T</given-names></name><name><surname>Reitz</surname><given-names>M</given-names></name></person-group><article-title>Metastatic renal carcinoma comprehensive prognostic system</article-title><source>Br J Cancer</source><year>2003</year><volume>88</volume><fpage>348</fpage><lpage>353</lpage><!--PubMed citation query: 'Br J Cancer||88|348||bib4|'--><pub-id pub-id-type="pmid">12569375</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Inflammation and cancer: back to Virchow</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>539</fpage><lpage>545</lpage><!--PubMed citation query: 'Lancet||357|539||bib5|'--><pub-id pub-id-type="pmid">11229684</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Betten</surname><given-names>A</given-names></name><name><surname>Dahlgren</surname><given-names>C</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name></person-group><article-title>Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met</article-title><source>Scand J Immunol</source><year>2003</year><volume>58</volume><fpage>321</fpage><lpage>326</lpage><!--PubMed citation query: 'Scand J Immunol||58|321||bib6|'--><pub-id pub-id-type="pmid">12950678</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brune</surname><given-names>M</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name></person-group><article-title>Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia</article-title><source>Br J Haematol</source><year>1996</year><volume>92</volume><fpage>620</fpage><lpage>626</lpage><!--PubMed citation query: 'Br J Haematol||92|620||bib7|'--><pub-id pub-id-type="pmid">8616026</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Yao</surname><given-names>PL</given-names></name><name><surname>Yuan</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Shun</surname><given-names>CT</given-names></name><name><surname>Tsai</surname><given-names>MF</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name></person-group><article-title>Tumor-associated macrophages: the double-edged sword in cancer progression</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>953</fpage><lpage>964</lpage><!--PubMed citation query: 'J Clin Oncol||23|953||bib8|'--><pub-id pub-id-type="pmid">15598976</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammatory cells and cancer: think different</article-title><source>J Exp Med</source><year>2001</year><volume>193</volume><fpage>F23</fpage><lpage>F26</lpage><!--PubMed citation query: 'J Exp Med||193|F23||bib9|'--><pub-id pub-id-type="pmid">11257144</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>860</fpage><lpage>867</lpage><!--PubMed citation query: 'Nature||420|860||bib10|'--><pub-id pub-id-type="pmid">12490959</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donskov</surname><given-names>F</given-names></name><name><surname>Bennedsgaard</surname><given-names>KM</given-names></name><name><surname>Hokland</surname><given-names>M</given-names></name><name><surname>Marcussen</surname><given-names>N</given-names></name><name><surname>Fisker</surname><given-names>R</given-names></name><name><surname>Madsen</surname><given-names>HH</given-names></name><name><surname>Fode</surname><given-names>K</given-names></name><name><surname>von der Maase</surname><given-names>H</given-names></name></person-group><article-title>Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma</article-title><source>Cancer Immunol Immunother</source><year>2004a</year><volume>53</volume><fpage>729</fpage><lpage>739</lpage><!--PubMed citation query: 'Cancer Immunol Immunother||53|729||bib11|'--><pub-id pub-id-type="pmid">15088127</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donskov</surname><given-names>F</given-names></name><name><surname>Bennedsgaard</surname><given-names>KM</given-names></name><name><surname>von der Maase</surname><given-names>H</given-names></name><name><surname>Marcussen</surname><given-names>N</given-names></name><name><surname>Fisker</surname><given-names>R</given-names></name><name><surname>Jensen</surname><given-names>JJ</given-names></name><name><surname>Naredi</surname><given-names>P</given-names></name><name><surname>Hokland</surname><given-names>M</given-names></name></person-group><article-title>Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival</article-title><source>Br J Cancer</source><year>2002a</year><volume>87</volume><fpage>194</fpage><lpage>201</lpage><!--PubMed citation query: 'Br J Cancer||87|194||bib12|'--><pub-id pub-id-type="pmid">12107842</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donskov</surname><given-names>F</given-names></name><name><surname>Middleton</surname><given-names>M</given-names></name><name><surname>Fode</surname><given-names>K</given-names></name><name><surname>Meldgaard</surname><given-names>P</given-names></name><name><surname>Mansoor</surname><given-names>W</given-names></name><name><surname>Lawrance</surname><given-names>J</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Nellemann</surname><given-names>H</given-names></name><name><surname>von der Maase</surname><given-names>H</given-names></name></person-group><article-title>Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><fpage>757</fpage><lpage>762</lpage><!--PubMed citation query: 'Br J Cancer||93|757||bib13|'--><pub-id pub-id-type="pmid">16136045</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donskov</surname><given-names>F</given-names></name><name><surname>von der Maase</surname><given-names>H</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name><name><surname>Stierner</surname><given-names>U</given-names></name><name><surname>Wersall</surname><given-names>P</given-names></name><name><surname>Nellemann</surname><given-names>H</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Engman</surname><given-names>K</given-names></name><name><surname>Naredi</surname><given-names>P</given-names></name></person-group><article-title>Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study</article-title><source>Ann Oncol</source><year>2002b</year><volume>13</volume><fpage>441</fpage><lpage>449</lpage><!--PubMed citation query: 'Ann Oncol||13|441||bib14|'--><pub-id pub-id-type="pmid">11996477</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donskov</surname><given-names>F</given-names></name><name><surname>von der Maase</surname><given-names>H</given-names></name><name><surname>Marcussen</surname><given-names>N</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S</given-names></name><name><surname>Madsen</surname><given-names>HH</given-names></name><name><surname>Jensen</surname><given-names>JJ</given-names></name><name><surname>Hokland</surname><given-names>M</given-names></name></person-group><article-title>Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no <italic>in vivo</italic> effect of Fas ligand tumor counterattack</article-title><source>Clin Cancer Res</source><year>2004b</year><volume>10</volume><fpage>7911</fpage><lpage>7916</lpage><!--PubMed citation query: 'Clin Cancer Res||10|7911||bib15|'--><pub-id pub-id-type="pmid">15585624</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finke</surname><given-names>JH</given-names></name><name><surname>Zea</surname><given-names>AH</given-names></name><name><surname>Stanley</surname><given-names>J</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Mizoguchi</surname><given-names>H</given-names></name><name><surname>Tubbs</surname><given-names>RR</given-names></name><name><surname>Wiltrout</surname><given-names>RH</given-names></name><name><surname>O'Shea</surname><given-names>JJ</given-names></name><name><surname>Kudoh</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name></person-group><article-title>Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>5613</fpage><lpage>5616</lpage><!--PubMed citation query: 'Cancer Res||53|5613||bib16|'--><pub-id pub-id-type="pmid">8242613</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gundersen</surname><given-names>HJ</given-names></name><name><surname>Bendtsen</surname><given-names>TF</given-names></name><name><surname>Korbo</surname><given-names>L</given-names></name><name><surname>Marcussen</surname><given-names>N</given-names></name><name><surname>Moller</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>K</given-names></name><name><surname>Nyengaard</surname><given-names>JR</given-names></name><name><surname>Pakkenberg</surname><given-names>B</given-names></name><name><surname>Sorensen</surname><given-names>FB</given-names></name><name><surname>Vesterby</surname><given-names>A</given-names></name></person-group><article-title>Some new, simple and efficient stereological methods and their use in pathological research and diagnosis</article-title><source>APMIS</source><year>1988</year><volume>96</volume><fpage>379</fpage><lpage>394</lpage><!--PubMed citation query: 'APMIS||96|379||bib17|'--><pub-id pub-id-type="pmid">3288247</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The hallmarks of cancer</article-title><source>Cell</source><year>2000</year><volume>100</volume><fpage>57</fpage><lpage>70</lpage><!--PubMed citation query: 'Cell||100|57||bib18|'--><pub-id pub-id-type="pmid">10647931</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>M</given-names></name><name><surname>Asea</surname><given-names>A</given-names></name><name><surname>Ersson</surname><given-names>U</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name></person-group><article-title>Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites</article-title><source>J Immunol</source><year>1996</year><volume>156</volume><fpage>42</fpage><lpage>47</lpage><!--PubMed citation query: 'J Immunol||156|42||bib19|'--><pub-id pub-id-type="pmid">8598491</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>M</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name><name><surname>Brune</surname><given-names>M</given-names></name><name><surname>Mellqvist</surname><given-names>UH</given-names></name><name><surname>Naredi</surname><given-names>P</given-names></name><name><surname>Betten</surname><given-names>A</given-names></name><name><surname>Gehlsen</surname><given-names>KR</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name></person-group><article-title>Histamine protects T cells and natural killer cells against oxidative stress</article-title><source>J Interferon Cytokine Res</source><year>1999</year><volume>19</volume><fpage>1135</fpage><lpage>1144</lpage><!--PubMed citation query: 'J Interferon Cytokine Res||19|1135||bib20|'--><pub-id pub-id-type="pmid">10547153</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellstrand</surname><given-names>K</given-names></name></person-group><article-title>Histamine in cancer immunotherapy: a preclinical background</article-title><source>Semin Oncol</source><year>2002</year><volume>29</volume><fpage>35</fpage><lpage>40</lpage><!--PubMed citation query: 'Semin Oncol||29|35||bib21|'--></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Asea</surname><given-names>A</given-names></name><name><surname>Dahlgren</surname><given-names>C</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name></person-group><article-title>Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites</article-title><source>J Immunol</source><year>1994</year><volume>153</volume><fpage>4940</fpage><lpage>4947</lpage><!--PubMed citation query: 'J Immunol||153|4940||bib22|'--><pub-id pub-id-type="pmid">7963557</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Asea</surname><given-names>A</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name></person-group><article-title>Role of histamine in natural killer cell-mediated resistance against tumor cells</article-title><source>J Immunol</source><year>1990</year><volume>145</volume><fpage>4365</fpage><lpage>4370</lpage><!--PubMed citation query: 'J Immunol||145|4365||bib23|'--><pub-id pub-id-type="pmid">2147942</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name></person-group><article-title>Histamine H2-receptor-mediated regulation of human natural killer cell activity</article-title><source>J Immunol</source><year>1986</year><volume>137</volume><fpage>656</fpage><lpage>660</lpage><!--PubMed citation query: 'J Immunol||137|656||bib24|'--><pub-id pub-id-type="pmid">3722819</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Hermodsson</surname><given-names>S</given-names></name></person-group><article-title>Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2</article-title><source>Int Arch Allergy Appl Immunol</source><year>1990</year><volume>92</volume><fpage>379</fpage><lpage>389</lpage><!--PubMed citation query: 'Int Arch Allergy Appl Immunol||92|379||bib25|'--><pub-id pub-id-type="pmid">2150668</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herberman</surname><given-names>RB</given-names></name></person-group><article-title>Cancer immunotherapy with natural killer cells</article-title><source>Semin Oncol</source><year>2002</year><volume>29</volume><fpage>27</fpage><lpage>30</lpage><!--PubMed citation query: 'Semin Oncol||29|27||bib26|'--></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>GG</given-names></name><name><surname>Geertsen</surname><given-names>PF</given-names></name><name><surname>von der Maase</surname><given-names>H</given-names></name><name><surname>Zeuthen</surname><given-names>J</given-names></name></person-group><article-title>Interleukin-2 dose, blood monocyte and CD25&#x0002b; lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma</article-title><source>Cancer Immunol Immunother</source><year>1991</year><volume>34</volume><fpage>111</fpage><lpage>114</lpage><!--PubMed citation query: 'Cancer Immunol Immunother||34|111||bib27|'--><pub-id pub-id-type="pmid">1760814</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>K</given-names></name><name><surname>Salazar-Onfray</surname><given-names>F</given-names></name><name><surname>Petersson</surname><given-names>M</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Masucci</surname><given-names>G</given-names></name><name><surname>Wasserman</surname><given-names>K</given-names></name><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>P</given-names></name><name><surname>Kiessling</surname><given-names>R</given-names></name></person-group><article-title>Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity</article-title><source>Eur J Immunol</source><year>1996</year><volume>26</volume><fpage>1308</fpage><lpage>1313</lpage><!--PubMed citation query: 'Eur J Immunol||26|1308||bib28|'--><pub-id pub-id-type="pmid">8647210</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>EY</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group><article-title>Role of infiltrated leucocytes in tumour growth and spread</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><fpage>2053</fpage><lpage>2058</lpage><!--PubMed citation query: 'Br J Cancer||90|2053||bib29|'--><pub-id pub-id-type="pmid">15164120</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>HE</given-names></name><name><surname>Kirchner</surname><given-names>H</given-names></name><name><surname>Atzpodien</surname><given-names>J</given-names></name></person-group><article-title>Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients</article-title><source>J Urol</source><year>1996</year><volume>155</volume><fpage>19</fpage><lpage>25</lpage><!--PubMed citation query: 'J Urol||155|19||bib30|'--><pub-id pub-id-type="pmid">7490829</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lurie</surname><given-names>Y</given-names></name><name><surname>Nevens</surname><given-names>F</given-names></name><name><surname>Aprosina</surname><given-names>ZG</given-names></name><name><surname>Fedorova</surname><given-names>TA</given-names></name><name><surname>Kalinin</surname><given-names>AV</given-names></name><name><surname>Klimova</surname><given-names>EA</given-names></name><name><surname>Ilan</surname><given-names>Y</given-names></name><name><surname>Maevskaya</surname><given-names>MV</given-names></name><name><surname>Warnes</surname><given-names>TW</given-names></name><name><surname>Yuschuk</surname><given-names>ND</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name><name><surname>Gehlsen</surname><given-names>KR</given-names></name></person-group><article-title>A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C</article-title><source>J Viral Hepat</source><year>2002</year><volume>9</volume><fpage>346</fpage><lpage>353</lpage><!--PubMed citation query: 'J Viral Hepat||9|346||bib31|'--><pub-id pub-id-type="pmid">12225329</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malmberg</surname><given-names>KJ</given-names></name></person-group><article-title>Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape</article-title><source>Cancer Immunol Immunother</source><year>2004</year><volume>53</volume><fpage>879</fpage><lpage>892</lpage><!--PubMed citation query: 'Cancer Immunol Immunother||53|879||bib32|'--><pub-id pub-id-type="pmid">15338206</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Regan</surname><given-names>MM</given-names></name><name><surname>Clark</surname><given-names>JI</given-names></name><name><surname>Flaherty</surname><given-names>LE</given-names></name><name><surname>Weiss</surname><given-names>GR</given-names></name><name><surname>Logan</surname><given-names>TF</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>MS</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Ernstoff</surname><given-names>MS</given-names></name><name><surname>Tretter</surname><given-names>CP</given-names></name><name><surname>Urba</surname><given-names>WJ</given-names></name><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Margolin</surname><given-names>KA</given-names></name><name><surname>Mier</surname><given-names>JW</given-names></name><name><surname>Gollob</surname><given-names>JA</given-names></name><name><surname>Dutcher</surname><given-names>JP</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name></person-group><article-title>Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>133</fpage><lpage>141</lpage><!--PubMed citation query: 'J Clin Oncol||23|133||bib33|'--><pub-id pub-id-type="pmid">15625368</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mellqvist</surname><given-names>UH</given-names></name><name><surname>Wallhult</surname><given-names>E</given-names></name><name><surname>Brune</surname><given-names>M</given-names></name><name><surname>Jacobsson</surname><given-names>S</given-names></name><name><surname>Hellstrand</surname><given-names>K</given-names></name></person-group><article-title>Histamine dihydrochloride, interleukin-2 and interferon-alfa in multiple myeloma</article-title><source>Int J Immunother</source><year>1999</year><volume>15</volume><fpage>125</fpage><lpage>130</lpage><!--PubMed citation query: 'Int J Immunother||15|125||bib34|'--></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Hoogstraten</surname><given-names>B</given-names></name><name><surname>Staquet</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>A</given-names></name></person-group><article-title>Reporting results of cancer treatment</article-title><source>Cancer</source><year>1981</year><volume>47</volume><fpage>207</fpage><lpage>214</lpage><!--PubMed citation query: 'Cancer||47|207||bib35|'--><pub-id pub-id-type="pmid">7459811</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name><name><surname>Bacik</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>W</given-names></name><name><surname>Amsterdam</surname><given-names>A</given-names></name><name><surname>Ferrara</surname><given-names>J</given-names></name></person-group><article-title>Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2530</fpage><lpage>2540</lpage><!--PubMed citation query: 'J Clin Oncol||17|2530||bib36|'--><pub-id pub-id-type="pmid">10561319</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>C</given-names></name><name><surname>Giannoudis</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name></person-group><article-title>Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>2224</fpage><lpage>2234</lpage><!--PubMed citation query: 'Blood||104|2224||bib37|'--><pub-id pub-id-type="pmid">15231578</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Gomez</surname><given-names>F</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Buclon</surname><given-names>M</given-names></name><name><surname>Perol</surname><given-names>D</given-names></name><name><surname>Lasset</surname><given-names>C</given-names></name></person-group><article-title>Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>1460</fpage><lpage>1468</lpage><!--PubMed citation query: 'Ann Oncol||13|1460||bib38|'--><pub-id pub-id-type="pmid">12196373</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Lasset</surname><given-names>C</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Savary</surname><given-names>J</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Mercatello</surname><given-names>A</given-names></name><name><surname>Peny</surname><given-names>J</given-names></name><name><surname>Mousseau</surname><given-names>M</given-names></name><name><surname>Philip</surname><given-names>T</given-names></name><name><surname>Tursz</surname><given-names>T</given-names></name></person-group><article-title>Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1272</fpage><lpage>1278</lpage><!--PubMed citation query: 'N Engl J Med||338|1272||bib39|'--><pub-id pub-id-type="pmid">9562581</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Byrne</surname><given-names>KJ</given-names></name><name><surname>Dalgleish</surname><given-names>AG</given-names></name></person-group><article-title>Chronic immune activation and inflammation as the cause of malignancy</article-title><source>Br J Cancer</source><year>2001</year><volume>85</volume><fpage>473</fpage><lpage>483</lpage><!--PubMed citation query: 'Br J Cancer||85|473||bib40|'--><pub-id pub-id-type="pmid">11506482</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group><article-title>Tumour-educated macrophages promote tumour progression and metastasis</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>71</fpage><lpage>78</lpage><!--PubMed citation query: 'Nat Rev Cancer||4|71||bib41|'--><pub-id pub-id-type="pmid">14708027</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Progress in human tumour immunology and immunotherapy</article-title><source>Nature</source><year>2001</year><volume>411</volume><fpage>380</fpage><lpage>384</lpage><!--PubMed citation query: 'Nature||411|380||bib42|'--><pub-id pub-id-type="pmid">11357146</pub-id></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Muul</surname><given-names>LM</given-names></name><name><surname>Leitman</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>AE</given-names></name><name><surname>Ettinghausen</surname><given-names>SE</given-names></name><name><surname>Matory</surname><given-names>YL</given-names></name><name><surname>Skibber</surname><given-names>JM</given-names></name><name><surname>Shiloni</surname><given-names>E</given-names></name><name><surname>Vetto</surname><given-names>JT</given-names></name></person-group><article-title>Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer</article-title><source>N Engl J Med</source><year>1985</year><volume>313</volume><fpage>1485</fpage><lpage>1492</lpage><!--PubMed citation query: 'N Engl J Med||313|1485||bib43|'--><pub-id pub-id-type="pmid">3903508</pub-id></citation></ref><ref id="bib44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samlowski</surname><given-names>WE</given-names></name><name><surname>Petersen</surname><given-names>R</given-names></name><name><surname>Cuzzocrea</surname><given-names>S</given-names></name><name><surname>Macarthur</surname><given-names>H</given-names></name><name><surname>Burton</surname><given-names>D</given-names></name><name><surname>McGregor</surname><given-names>JR</given-names></name><name><surname>Salvemini</surname><given-names>D</given-names></name></person-group><article-title>A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>750</fpage><lpage>755</lpage><!--PubMed citation query: 'Nat Med||9|750||bib44|'--><pub-id pub-id-type="pmid">12730689</pub-id></citation></ref><ref id="bib45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Larsen</surname><given-names>S</given-names></name><name><surname>Bastholt</surname><given-names>L</given-names></name><name><surname>Fode</surname><given-names>K</given-names></name><name><surname>Rytter</surname><given-names>C</given-names></name><name><surname>von der Maase</surname><given-names>H</given-names></name></person-group><article-title>A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>1919</fpage><lpage>1924</lpage><!--PubMed citation query: 'Ann Oncol||13|1919||bib45|'--><pub-id pub-id-type="pmid">12453861</pub-id></citation></ref><ref id="bib46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seaman</surname><given-names>WE</given-names></name><name><surname>Gindhart</surname><given-names>TD</given-names></name><name><surname>Blackman</surname><given-names>MA</given-names></name><name><surname>Dalal</surname><given-names>B</given-names></name><name><surname>Talal</surname><given-names>N</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Suppression of natural killing <italic>in vitro</italic> by monocytes and polymorphonuclear leukocytes: requirement for reactive metabolites of oxygen</article-title><source>J Clin Invest</source><year>1982</year><volume>69</volume><fpage>876</fpage><lpage>888</lpage><!--PubMed citation query: 'J Clin Invest||69|876||bib46|'--><pub-id pub-id-type="pmid">7076851</pub-id></citation></ref><ref id="bib47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tartour</surname><given-names>E</given-names></name><name><surname>Latour</surname><given-names>S</given-names></name><name><surname>Mathiot</surname><given-names>C</given-names></name><name><surname>Thiounn</surname><given-names>N</given-names></name><name><surname>Mosseri</surname><given-names>V</given-names></name><name><surname>Joyeux</surname><given-names>I</given-names></name><name><surname>D'Enghien</surname><given-names>CD</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Debre</surname><given-names>B</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name></person-group><article-title>Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function</article-title><source>Int J Cancer</source><year>1995</year><volume>63</volume><fpage>205</fpage><lpage>212</lpage><!--PubMed citation query: 'Int J Cancer||63|205||bib47|'--><pub-id pub-id-type="pmid">7591205</pub-id></citation></ref><ref id="bib48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vakkila</surname><given-names>J</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name></person-group><article-title>Inflammation and necrosis promote tumour growth</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>641</fpage><lpage>648</lpage><!--PubMed citation query: 'Nat Rev Immunol||4|641||bib48|'--><pub-id pub-id-type="pmid">15286730</pub-id></citation></ref><ref id="bib49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyckoff</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>EY</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pixley</surname><given-names>F</given-names></name><name><surname>Stanley</surname><given-names>ER</given-names></name><name><surname>Graf</surname><given-names>T</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name><name><surname>Segall</surname><given-names>J</given-names></name><name><surname>Condeelis</surname><given-names>J</given-names></name></person-group><article-title>A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>7022</fpage><lpage>7029</lpage><!--PubMed citation query: 'Cancer Res||64|7022||bib49|'--><pub-id pub-id-type="pmid">15466195</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Peripheral blood monocytes, neutrophils and NK cells (CD16<sup>&#x0002b;</sup>56<sup>&#x0002b;</sup>) as prognostic factors for IL-2 based immunotherapy. High levels of monocytes and neutrophils were correlated with short survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="94-6602937f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Peripheral blood neutrophils, monocytes and NK cells as prognostic factors stratified for treatment assignment. Kaplan&#x02013;Meier plots at baseline and week 8 in patients with metastatic renal cell carcinoma treated with interleukin-2 and HDC (&#x02014;) or IL-2 alone (-&#x02009;-&#x02009;-&#x02009;-) concerning survival for (<bold>A</bold>) monocytes (<bold>B</bold>) neutrophils and (<bold>C</bold>) NK cells (CD16<sup>&#x0002b;</sup>56<sup>&#x0002b;</sup>). IL-2&#x0002f;HDC treatment resulted in long-term survival in patients with low numbers of monocytes and neutrophils and patients with high number of NK cells in the peripheral blood. Vertical and horizontal axes, the survival probability and months of follow-up, respectively. Tick marks (&#x02223;) indicate last date of follow-up. The hazard ratio (HR) refers to IL-2&#x0002f;HDC relative to IL-2 alone. CI, confidence interval.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="94-6602937f2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>Potential histamine effect on circulating monocytes during IL-2-based treatment, assessed <italic>in situ</italic>. Treatment with IL-2&#x0002f;HDC (white boxes) resulted in unchanged number of circulating monocytes in patients with complete response (CR), partial responses (PR) and stable disease (SD) compared with baseline values, whereas treatment with IL-2-alone (black boxes) did not prevent a significant increased number compared with baseline. All patient with progressive disease (PD) had significantly increased monocyte numbers at weeks 3 and 8 compared with baseline, irrespective of the treatment group. Vertical and horizontal axes, 10<sup>9</sup>&#x02009;cells&#x02009;l<sup>&#x02212;1</sup> and response to immunotherapy, respectively. The box plots represent the median (solid black line), the 25th and the 75th percentiles (boxed) and the 10th and the 90th percentiles (error bars). &#x02018;O' indicate outliers. &#x02018;<sub><sup>&#x0002a;</sup></sub>' indicate extremes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="94-6602937f3"/></fig><fig id="fig4"><label>Figure 4</label><caption><p>Potential histamine effect on intratumoral NK, T-cells and macrophages during IL-2 based treatment, assessed <italic>in situ</italic>. Treatment with IL-2&#x0002f;HDC resulted in significantly higher numbers of intratumoral NK cells and CD8<sup>&#x0002b;</sup>T cells and unchanged numbers of intratumoral macrophages during treatment compared with baseline. IL-2 alone did not prevent a significantly higher number of intratumoral macrophages but did not result in increased intratumoral NK or T cells compared with baseline. The box plots represent the median (solid black line), the 25th and the 75th percentiles (boxed) and the 10th and the 90th percentiles (error bars). &#x02018;O' indicate outliers. &#x02018;<sub><sup>&#x0002a;</sup></sub>' indicate extremes. Vertical and horizontal axes, the median number of cells&#x02009;mm<sup>&#x02212;2</sup> tumour tissue and therapy administered, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="94-6602937f4"/></fig><fig id="fig5"><label>Figure 5</label><caption><p>Correlation between <italic>in vitro</italic> cytotoxicity and NK cells, neutrophils and monocytes. A significantly positive correlation between blood CD16<sup>&#x0002b;</sup>CD56<sup>&#x0002b;</sup> NK cells and cytotoxicity was observed. In contrast, there was a significantly negative correlation between blood neutrophils and cytotoxicity and also between blood monocytes and cytotoxicity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="94-6602937f5"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Number of tumour biopsies and blood samples</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Week</bold></th><th align="center" valign="top" charoff="50"><bold>0</bold></th><th align="center" valign="top" charoff="50"><bold>3</bold></th><th align="center" valign="top" charoff="50"><bold>8</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Number of patients on-treatment at the indicated time point</td><td align="center" valign="top" charoff="50">59</td><td align="center" valign="top" charoff="50">57</td><td align="center" valign="top" charoff="50">55</td></tr><tr><td align="left" valign="top" charoff="50">Number blood samples</td><td align="center" valign="top" charoff="50">59 (100&#x00025;)</td><td align="center" valign="top" charoff="50">54 (95&#x00025;)</td><td align="center" valign="top" charoff="50">52 (95&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Number tumour biopsies</td><td align="center" valign="top" charoff="50">44 (75&#x00025;)</td><td align="center" valign="top" charoff="50">29 (51&#x00025;)</td><td align="center" valign="top" charoff="50">25 (45&#x00025;)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>Percentages indicate the number of samples obtained compared to the number of patients on-treatment at the indicated time point. The main reasons for not having a biopsy were withdrawal of consent and tumour necrosis. Not having a blood sample was due to logistic reasons.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Baseline patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="center"/><col align="char" char="."/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="2" align="center" valign="top" char="." charoff="50"><bold>IL-2 plus Histamine Study Group <italic>N</italic>&#x0003d;30</bold></th><th colspan="2" align="center" valign="top" char="." charoff="50"><bold>IL-2 alone Control Group <italic>N</italic>&#x0003d;29</bold></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="char" valign="top" char="." charoff="50"><bold><italic>N</italic></bold></th><th align="center" valign="top" charoff="50"><bold>&#x00025;</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>N</italic></bold></th><th align="center" valign="top" charoff="50"><bold>&#x00025;</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Median age, years (range)</td><td align="char" valign="top" char="." charoff="50">55</td><td align="center" valign="top" charoff="50">(31&#x02013;69)</td><td align="char" valign="top" char="." charoff="50">60</td><td align="center" valign="top" charoff="50">(36&#x02013;69)</td></tr><tr><td align="left" valign="top" charoff="50">Male</td><td align="char" valign="top" char="." charoff="50">24</td><td align="center" valign="top" charoff="50">80</td><td align="char" valign="top" char="." charoff="50">16</td><td align="center" valign="top" charoff="50">55</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Karnofsky performance status</italic></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;100</td><td align="char" valign="top" char="." charoff="50">16</td><td align="center" valign="top" charoff="50">53</td><td align="char" valign="top" char="." charoff="50">12</td><td align="center" valign="top" charoff="50">41</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;90</td><td align="char" valign="top" char="." charoff="50">10</td><td align="center" valign="top" charoff="50">33</td><td align="char" valign="top" char="." charoff="50">13</td><td align="center" valign="top" charoff="50">45</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;80</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">7</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;70</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">7</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Metastasis-free interval &#x02a7d;1 year</td><td align="char" valign="top" char="." charoff="50">22</td><td align="center" valign="top" charoff="50">73</td><td align="char" valign="top" char="." charoff="50">20</td><td align="center" valign="top" charoff="50">69</td></tr><tr><td align="left" valign="top" charoff="50">Baseline blood neutrophils</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Median (&#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>), (range)</td><td align="char" valign="top" char="." charoff="50">5.43</td><td align="center" valign="top" charoff="50">(2.61&#x02013;15.91)</td><td align="char" valign="top" char="." charoff="50">5.54</td><td align="center" valign="top" charoff="50">(2.01&#x02013;10.33)</td></tr><tr><td align="left" valign="top" charoff="50">Baseline blood monocytes</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Median (&#x000d7; 10<sup>9&#x02009;</sup>l<sup>&#x02212;1</sup>), (range)</td><td align="char" valign="top" char="." charoff="50">0.74</td><td align="center" valign="top" charoff="50">(0.35&#x02013;1.51)</td><td align="char" valign="top" char="." charoff="50">0.69</td><td align="center" valign="top" charoff="50">(0.32&#x02013;1.11)</td></tr><tr><td align="left" valign="top" charoff="50">Baseline blood CD16<sup>&#x0002b;</sup>56<sup>&#x0002b;</sup> NK-cells</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Median (&#x000d7; 10<sup>9</sup>&#x02009;l<sup>&#x02212;1</sup>), (range)</td><td align="char" valign="top" char="." charoff="50">0.1</td><td align="center" valign="top" charoff="50">(0.02&#x02013;0.36)</td><td align="char" valign="top" char="." charoff="50">0.06</td><td align="center" valign="top" charoff="50">(0.01&#x02013;0.39)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Prior therapy</italic></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nephrectomy</td><td align="char" valign="top" char="." charoff="50">17</td><td align="center" valign="top" charoff="50">57</td><td align="char" valign="top" char="." charoff="50">18</td><td align="center" valign="top" charoff="50">62</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Excision of metastatic lesions</td><td align="char" valign="top" char="." charoff="50">3</td><td align="center" valign="top" charoff="50">10</td><td align="char" valign="top" char="." charoff="50">1</td><td align="center" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Number of disease organ sites</italic></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">7</td><td align="char" valign="top" char="." charoff="50">3</td><td align="center" valign="top" charoff="50">10</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="char" valign="top" char="." charoff="50">7</td><td align="center" valign="top" charoff="50">23</td><td align="char" valign="top" char="." charoff="50">7</td><td align="center" valign="top" charoff="50">24</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3 or more</td><td align="char" valign="top" char="." charoff="50">21</td><td align="center" valign="top" charoff="50">70</td><td align="char" valign="top" char="." charoff="50">19</td><td align="center" valign="top" charoff="50">66</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Most common sites of disease</italic></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Primary kidney tumour</td><td align="char" valign="top" char="." charoff="50">13</td><td align="center" valign="top" charoff="50">43</td><td align="char" valign="top" char="." charoff="50">12</td><td align="center" valign="top" charoff="50">41</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Local recurrence kidney bed</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">13</td><td align="char" valign="top" char="." charoff="50">5</td><td align="center" valign="top" charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lung&#x0002f;pleura</td><td align="char" valign="top" char="." charoff="50">23</td><td align="center" valign="top" charoff="50">77</td><td align="char" valign="top" char="." charoff="50">22</td><td align="center" valign="top" charoff="50">76</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lung metastasis alone</td><td align="char" valign="top" char="." charoff="50">1</td><td align="center" valign="top" charoff="50">3</td><td align="char" valign="top" char="." charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lymph node</td><td align="char" valign="top" char="." charoff="50">21</td><td align="center" valign="top" charoff="50">70</td><td align="char" valign="top" char="." charoff="50">17</td><td align="center" valign="top" charoff="50">59</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="char" valign="top" char="." charoff="50">3</td><td align="center" valign="top" charoff="50">10</td><td align="char" valign="top" char="." charoff="50">7</td><td align="center" valign="top" charoff="50">24</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Bone</td><td align="char" valign="top" char="." charoff="50">11</td><td align="center" valign="top" charoff="50">37</td><td align="char" valign="top" char="." charoff="50">10</td><td align="center" valign="top" charoff="50">35</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Soft tissue</td><td align="char" valign="top" char="." charoff="50">5</td><td align="center" valign="top" charoff="50">17</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">14</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>MSKCC prognostic criteria</italic><sup>a</sup></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Favorable prognosis</td><td align="char" valign="top" char="." charoff="50">6</td><td align="center" valign="top" charoff="50">20</td><td align="char" valign="top" char="." charoff="50">5</td><td align="center" valign="top" charoff="50">17</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Intermediate prognosis</td><td align="char" valign="top" char="." charoff="50">20</td><td align="center" valign="top" charoff="50">63</td><td align="char" valign="top" char="." charoff="50">18</td><td align="center" valign="top" charoff="50">62</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Poor prognosis</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">13</td><td align="char" valign="top" char="." charoff="50">6</td><td align="center" valign="top" charoff="50">21</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote2"><label>a</label><p>Memorial Sloan&#x02013;Kettering Cancer Center (<xref ref-type="other" rid="bib36">Motzer <italic>et al</italic>, 1999</xref>).</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


